John Flynn, M.D.
Abstract #756: Impact of Infliximab on Costs of Ankylosing Spondylitis: Results of Eres Study, and Economic Evaluation Based on One-Year Randomized Controlled Trial in a One-Year Open-Label Extension Study
Abstract #2017: Treatment With Adalimumab Reduces Signs and Symptoms and Induces Partial Remission in Patients With Ankylosing Spondylitis (AS): One-Year Results From ATLAS.
Abstract #1116: Efficacy of Lower Dose Infliximab in Active Ankylosing Spondylitis: Interim Results of a Canadian Study
Abstract #1115: New Biomarkers in Monitoring Disease Activity in Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with TNF-a Inhibitors
Abstract #2016: Comparison of the Effect of Infliximab on Inflammation and Bone Formation Biomarkers and Association With Clinical Response in Ankylosing Spondylitis and Psoriatic Arthritis
Abstract #2021: CASPAR Criteria Are Sensitive in Early Psoriatic Arthritis
Abstract #2058: The Relationship Between the Extensor Tendon Enthesis and Distal Interphalangeal Joint Disease in Psoriatic Arthritis: High-Resolution MRI and Histological Study
Abstract #199: The Role of MRI Imaging in the Diagnosis of Early Inflammatory Back Pain
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.
